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Astragaloside II promotes intestinal 
epithelial repair by enhancing 
L-arginine uptake and activating 
the mTOR pathway
Shih-Yu Lee1, Wei-Cheng Tsai2, Jung-Chun Lin3, Blerina Ahmetaj-Shala4, Su-Feng Huang2, 
Wen-Liang Chang5 & Tsu-Chung Chang2,6,7
Astragaloside II (AS II) extracted from Astragalus membranaceus has been reported to promote 
tissue wound repair. However, the effect of AS II on inflammatory bowel disease is unknown. We 
investigated the effects and mechanism of AS II on intestinal wound healing in both in vitro and in vivo 
models. Human intestinal Caco-2 cells were treated with multiple concentrations of AS II to assess 
cell proliferation, scratch wound closure, L-arginine uptake, cationic amino acid transporter activity, 
and activation of the mTOR signaling pathway. These effects were also measured in a mouse model 
of colitis. AS II promoted wound closure and increased cell proliferation, L-arginine uptake, CAT1 and 
CAT2 protein levels, total protein synthesis, and phosphorylation of mTOR, S6K, and 4E-BP1 in Caco-2 
cells. These effects were suppressed by lysine or rapamycin treatment, suggesting that the enhanced 
arginine uptake mediates AS II-induced wound healing. Similar results were also observed in vivo. Our 
findings indicate that AS II can contribute to epithelial barrier repair following intestinal injury, and may 
offer a therapeutic avenue in treating irritable bowel disease.
Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder, which can manifest as ulcerative colitis 
and Crohn’s disease1. Clinical symptoms include weight loss, abdominal pain, diarrhea, and bleeding2, and con-
tinuous mucosal inflammation can lead to intestinal fibrosis and may subsequently progress and develop into 
colon cancer3. The prevalence of IBD has been reported as 200 per 100,000 in the US, and this number is increas-
ing; IBD has now become a global health issue as more countries are adopting a Western diet4. Although the 
precise mechanisms of IBD are still unknown, most studies concur that IBD is associated with hereditary, infec-
tious, environmental, and auto-immune factors. The integrity of the intestinal epithelial barrier plays a role in 
IBD progression5. Recent studies have indicated that restoration of the epithelial barrier integrity is an important 
healing response in IBD and other intestinal disorders6–10. Thus, the repair of the intestinal epithelial barrier may 
be a promising therapeutic strategy in IBD. Current medications, such as non-steroidal anti-inflammatory drugs, 
steroids, and immunodulators, are limited in their application because of poor efficacy and adverse effects10. 
Therefore, a new effective therapy for IBD is needed.
Recovery of the epithelial barrier is crucial in the treatment of colitis. L-arginine (L-Arg) is involved in protein 
synthesis and regulation of many essential cellular functions, including immune response, hormone secretion, 
and wound healing11. In addition, L-Arg and its metabolite ornithine promote colonic epithelial wound repair by 
enhancing cell proliferation and collagen deposition12. L-Arg uptake has been shown to occur primarily by cati-
onic amino acid transporter 2 (CAT 2), and is an important process in the restoration of colonic epithelial cells10. 
This is also confirmed by evidence that L-Arg supplementation suppressed intestinal permeability and improved 
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IBD symptoms by enhancing wound healing in an IBD rodent model7. Protein metabolism in intestinal mucosa 
is essential for gut homeostasis and maintenance of the epithelial barrier13. L-Arg increases intestinal protein syn-
thesis and epithelial repair by activating the mechanistic target of rapamycin (mTOR) signaling pathway14. Once 
activated, mTOR phosphorylates its downstream targets, ribosomal protein S6 kinase (p70 S6K) and eukaryotic 
initiation factor 4E-binding protein 1 (4E-BP1), thereby promoting mRNA translation, protein synthesis, and cell 
growth15. In contrast, blockage of the mTOR pathway suppresses intestinal cell migration16. In this way, L-Arg 
contributes to wound healing and protein synthesis, while significantly enhancing mTOR signaling; this pathway 
may be a promising agent in intestinal wound closure.
Radix Astragali is a well-known medicinal herb for reinforcing Qi (the vital energy) in traditional Chinese 
medicine, which considers it to possess immunomodulatory, wound-healing, anti-inflammatory, anti-aging, 
anti-oxidant, and hypoglycemic properties17. Astragalus membranaceus contains a variety of compounds, 
including polysaccharides, flavonoids, and saponins. Astragaloside II (AS II; Fig. 1A) is one of the major 
cycloartane-type triterpene glycosides extracted from Radix Astragali18, and has recently been reported to be a 
potential adjunctive agent in cancer chemotherapy19, enhancement of osteogenesis20, and modulation of T cell 
activation21. However, the effects and underlying mechanism of AS II on intestinal wound healing are unknown. 
In the present study, we examined the effect of AS II in repair and restoration of intestinal epithelial barrier func-
tion and the signaling mechanism involved, both in vitro and in vivo.
Results
AS II promotes cell proliferation and scratch wound closure in Caco-2 cells. We first investigated 
the effect of AS II on cell proliferation. AS II increased cell proliferation (fold-change compared with control: 
1.11 ± 0.03 for 0.01 μM, p < 0.05; 1.22 ± 0.03 for 0.1 μM, p < 0.001; 1.16 ± 0.03 for 1 μM, p < 0.001) (Fig. 1B). AS 
II improved scratch wound closure in Caco-2 cells in a time-dependent manner (Fig. 1C); the maximum effect of 
scratch wound closure was observed at 0.1 μM. Forty-eight hours after initiating the scratch wound assay, scratch 
wound percent closure increased from 30.77 ± 2.13 to 41.42 ± 2.09 (0.01 μM, p < 0.01), 42.17 ± 1.42 (0.1 μM, 
p < 0.001), and 39.79 ± 1.61 (1 μM, p < 0.01) (Fig. 1C).
AS II increases L-Arg uptake and CAT protein levels in Caco-2 cells. To assess the effects of AS II 
on L-Arg uptake, we treated Caco-2 cells with AS II. As shown in Fig. 2A, 0.1 μM of AS II significantly increased 
L-Arg cellular uptake between 0.5 and 24 hr compared with the control, reaching 104.73 ± 3.90 pmol/mg protein/
min 6 hr after treatment (p < 0.001). The stimulatory effect of AS II was observed in the concentrations tested; 
the greatest effect was seen in the 0.1-μM treatment (108.18 ± 8.02 pmol/mg protein/min, p < 0.001 compared 
with the control; Fig. 2B). To identify the L-Arg transporters involved, we measured the expression of CAT1 and 
CAT2, and found that 0.1 μM AS II significantly increased both CAT1 and CAT2 expression (Fig. 2C and D) 
between 6 and 48 hr after treatment. A higher concentration of AS II (1 μM) also increased CAT1 and CAT2 
protein levels (1.45 ± 0.18 fold-increase over control for CAT1, p < 0.05; 1.55 ± 0.05 fold-increase over control for 
CAT2, p < 0.05; Fig. 2E and F).
AS II activates the mTOR pathway and enhances protein synthesis in Caco-2 cells. We studied 
the effect of AS II on mTOR activation and protein synthesis. AS II (0.1 μM) increased phosphorylated mTOR 
Figure 1. Effects of astragaloside II (AS II) on cell proliferation and scratch wound closure in Caco-2 cells. 
(A) Chemical structure of AS II. (B) Caco-2 cells were treated with 0.01, 0.1, and 1 μM AS II for 24 hr. Cell 
proliferation was measured using a CCK-8 kit. (C) The Caco-2 cell monolayers were scratched and incubated 
with the indicated concentrations of AS II. Wound closure was photographed and quantified over time. Data 
represent mean ± SEM (n = 6). *p < 0.05, **p < 0.01, and ***p < 0.001 versus the untreated control.
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levels, especially 1 hr after treatment (1.44 ± 0.02 fold-increase over control, p < 0.01; Fig. 3A and B). AS II also 
promoted the phosphorylation of mTOR’s downstream targets S6K and 4EBP1, especially 3 and 6 hr after treat-
ment (p < 0.01 for p-S6K and p < 0.05 for p-4EBP1 compared with the control; Fig. 3A,C and D). We then inves-
tigated the effect of AS II on cellular protein synthesis. AS II significantly increased protein synthesis in both a 
time- and concentration-dependent manner (Fig. 3E and F). These findings indicate AS II increases both the 
mTOR signal pathway and protein synthesis in Caco-2 cells.
Lysine and rapamycin both suppress the effects of AS II on the mTOR signaling pathway. To 
investigate the roles of L-Arg uptake and mTOR signaling in the wound-healing activity of AS II, we used 
lysine (a competitive inhibitor of CAT1 and CAT2 for L-Arg uptake) and rapamycin (the mTORC1 inhibitor). 
Pretreatment with lysine reduced AS II-upregulated scratch wound closure (from 40.58 ± 1.48 to 32.10 ± 1.54%; 
p < 0.01; Fig. 4A), protein synthesis (from 120.60 ± 2.48 to 94.88 ± 2.09%; p < 0.001; Fig. 4B), p-mTOR (from 
1.18 to 0.93 fold-increase over control; Fig. 4C), and p-S6K (from 1.43 to 0.97 fold-increase over control; 
Fig. 4D). Rapamycin exerted similar effects on AS II-upregulated scratch wound closure (from 29.36 ± 1.01 to 
18.43 ± 0.52%; p < 0.05; Fig. 4E), protein synthesis (from 118.14 ± 1.49 to 92.20 ± 2.56% compared with con-
trol; p < 0.001; Fig. 4F), and p-S6K (from 1.71 ± 0.08 to 0.21 ± 0.17 fold-increase over control; p < 0.01; Fig. 4G). 
The results indicated that both upregulation of the L-Arg uptake and mTOR activation are necessary for AS 
II-mediated wound healing.
AS II attenuates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. To assess 
the in vivo effects of AS II, we established a TNBS-induced mouse model of colitis. We found that treatment 
with AS II attenuated TNBS-induced weight loss (from 85.75 ± 2.54 to 94.85 ± 1.78% compared with the control 
[100%], p < 0.01; Fig. 5A), and affected the length of the small intestine (from 28.46 ± 1.40 to 31.88 ± 0.85 cm, 
p < 0.05; Fig. 5B), length of the large intestine (from 5.40 ± 0.18 to 6.22 ± 0.22 cm, p < 0.05; Fig. 5C), and mye-
loperoxidase (MPO) activity in the small intestine (from 1.15 ± 0.30 to 0.35 ± 0.08 unit/mg protein, p < 0.01; 
Fig. 5D). MPO activity in the large intestine (Fig. 5E) and epithelial barrier permeability (Fig. 5F) were also meas-
ured, but did not differ statistically from the control. AS II significantly increased L-Arg uptake in the small intes-
tine (from 500.60 ± 64.17 to 731.29 ± 75.82 pmol/min/mg protein, p < 0.05; Fig. 5G). Slight but non-significant 
increase was observed in the colon (Fig. 5H). AS II also increased CAT1 and CAT2 levels in the small intestine 
(Fig. 5I) and CAT1 levels in the colon (Fig. 5J). Colon histology appeared altered (Fig. 5K).
Discussion
In this study, we examined the effects of AS II, one of the major bioactive components of A. membranaceus, on 
repair and restoration of intestinal epithelial barrier function, and investigated the signaling mechanism involved. 
We found that AS II can promote scratch wound closure, cell proliferation, and arginine uptake, and can induce 
Figure 2. Effects of astragaloside II (AS II) on L-arginine (L-Arg) uptake and cationic amino acid transporter 
(CAT) expression. Differentiated Caco-2 cells were incubated with AS II and then analyzed for L-Arg 
accumulation at the indicated time periods (A) and concentrations (B). CAT1 and CAT2 protein levels in 
Caco-2 cells were assessed by western blotting at different time points (C and D) and concentrations (E and F) 
of AS II treatment. Data represent mean ± SEM (n = 6 for L-Arg uptake, n = 3 for western blotting). *p < 0.05, 
**p < 0.01, and ***p < 0.001 versus the untreated control.
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the arginine transporters CAT1 and CAT2 in differentiated human intestinal Caco-2 cells. In addition, AS II 
enhanced the phosphorylation of mTOR, S6K, and 4E-BP1, while protein synthesis increased significantly. The 
effects of AS II on wound closure were also confirmed using L-lysine (a competitive inhibitor of L-Arg uptake) 
and rapamycin (a specific mTOR inhibitor), as both of these inhibitors suppressed the effect of AS II on wound 
closure. These results suggest that L-Arg uptake and mTOR signaling activation are involved in AS II-induced 
wound healing. The effect of 0.1 μM AS II was greater than that of 1 μM AS II on cell proliferation, wound closure, 
L-Arg uptake, CAT1 expression, and leucine incorporation. These findings indicate that 0.1 μM is an effective 
concentration. A 1-μM treatment appeared to exert adverse effects or to inhibit the beneficial effects. The higher 
concentration may induce or interfere with certain cellular activities. The dose independent activity has been 
reported in different natural product22. In a TNBS-induced mouse colitis model, AS II was shown to ameliorate 
the severity of colitis symptoms such as weight loss, reduction in intestinal length, intestinal inflammation, and 
increased mucosal permeability. AS II also increased intestinal L-Arg uptake and mucosal CAT protein levels. 
Our findings indicate that AS II promotes intestinal epithelial healing through increased L-Arg uptake and pro-
tein synthesis, which are likely mediated by the increased expression of L-Arg transporters and activation of the 
mTOR signaling pathway, respectively. Figure 6 displays our proposed mechanism of AS II action.
A recent strategy for managing IBD has been to improve the integrity of the intestinal epithelial barrier and 
prevent recurrence of intestinal inflammation, especially in Crohn’s disease23. In traditional Chinese medicine, 
Radix Astragali is a tonic herb used in a variety of inflammatory and immune diseases, as well as for wound 
Figure 3. Effects of astragaloside II (AS II) on the mTOR signaling pathway and on protein synthesis. Caco-2 
cells were incubated with 0.1 μM AS II and then harvested for western blotting (A). Levels of p-mTOR/mTOR 
(B), p-S6K/S6K (C), and p-4E-BP1/4E-BP1 (D) were quantified. Protein synthesis was assayed by [3H]-leucine 
incorporation and quantified by time (E) and concentration (at 24 hr, F). Data represent mean ± SEM (n = 3). 
*p < 0.05, **p < 0.01, and ***p < 0.001 versus the untreated control.
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Figure 4. Effects of L-lysine and rapamycin on wound closure and protein synthesis in astragaloside II (AS 
II)-treated Caco-2 cells. Cells were incubated with L-lysine (20 mM) or rapamycin (100 nM) 30 min prior to 
treatment with 0.1 μM AS II. Scratch wound closure and protein synthesis were quantified after 36 hr (A) and 
24 hr (B), respectively. Levels of p-mTOR/mTOR (C) and p-S6K/S6K (D) were analyzed in the L-lysine-treated 
cells. Similarly, scratch wound closure (E), protein synthesis (F), and p-S6K/S6K levels (G) were analyzed in 
the rapamycin-treated cells. Data represent mean ± SEM (n = 3). *p < 0.05 and **p < 0.01 versus the untreated 
control; #p < 0.05 versus the AS II-treated cells.
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Figure 5. Effects of astragaloside II (AS II) on a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced mouse 
model of colitis. (A) Body weight. (B) Length of the small intestine. (C) Length of the colon. Myeloperoxidase 
(MPO) activity was examined in both the small intestine (D) and the colon (E). (F) mucosal permeability. (G 
and H) L-arginine (L-Arg) uptake. (I and J) Levels of cationic amino acid transporters (CATs). (K) Histological 
examination was performed by photomicrography (original magnification at 40× and 100×). Data represent 
mean ± SEM (n = 6). *p < 0.05, ***p < 0.01, and ***p < 0.001 versus the untreated control; #p < 0.05 and 
##p < 0.01 versus the AS II-treated cells.
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healing21. In the present study, we showed that AS II can promote intestinal epithelial wound healing via the 
mTOR pathway in vitro and in vivo. IBD pathogenesis is a complex process, which involves the immune response 
and inflammation1. Crude extract of Radix Astragali has been shown to exert protective and anti-inflammatory 
effects in several animal models of colitis24–26. To our knowledge, this is the first study to report the beneficial 
effects of AS II, a major bioactive component of Astragalus, in a TNBS-induced animal model of colitis. Our find-
ings provide a better understanding of the therapeutic potential of Radix Astragali in IBD. We also showed that 
MPO activity was inhibited in AS II-treated mice, indicating its anti-inflammatory potential. Future work should 
assess whether AS II can attenuate IBD symptoms by modulating the immune response.
Astragalus products have been used as immunomodulatory and wound-healing agents in traditional Chinese 
medicine17. However, the detailed mechanisms and bioactive components are largely unknown. Radix Astragali 
contains a variety of compounds such as polysaccharides, flavonoids, isoflavonoids, and polyphenols. Among 
these, astragalosides have been shown to promote wound-healing activity in vitro and in vivo27. To date, most 
studies have focused on the pharmacological effects of AS IV, a major astragaloside, which has been shown to 
improve wound repair and diminish scarring in burn wounds28. However, few studies have investigated AS II’s 
effects on intestinal epithelial healing. The structure of AS II is similar to that of AS IV, apart from an additional 
acetyl group at C-2 of the xylose residues. We found that AS II improved intestinal epithelial repair by enhancing 
L-Arg uptake and activating the mTOR pathway. AS II has been shown to exert better T cell immune-stimulating 
effects than AS IV21. This suggests that AS II may be a more potent immune stimulator than AS IV. Current drugs 
indicated for IBD treatment include anti-inflammatory drugs, immunosuppressives, antibiotics, and biologic 
agents. These agents can cause side effects such as gastrointestinal symptoms, hepatotoxicity, and renal toxicity, 
limiting their clinical applications29. Radix Astragali is considered a top-grade herb in traditional Chinese medi-
cine, meaning a safe and nontoxic herbal medicine30. Astragalus supplementation (90 g daily) has been reported 
to have low toxicity and no significant adverse effects31. AS II may therefore be a safe and promising compound 
for treating IBD or immune disorders.
L-Arg has been shown to promote wound healing in skin, intestinal epithelial tissues, and in vivo IBD mod-
els7,32,33. In the present study, AS II improved L-Arg uptake in both cultured Caco-2 cells and colonic tissue, and 
increased CAT1 and CAT2 levels. Cellular uptake of L-Arg through CAT2 is important for colonic epithelial 
wound repair10. One study indicated that 12-O-tetradecanoylphorbol-13-acetate increased L-Arg uptake and 
CAT levels by activating the protein kinase C (PKC) signaling pathway in intestinal epithelial cells34. Whether 
AS II promotes CAT expression via the PKC signaling pathway requires further study. High doses of L-Arg sup-
plementation (500 mg/day) exacerbated colonic inflammation and fibrosis in rats because of excessive nitric 
oxide production and collagen deposition35. A study in humans36 reported that serum levels of L-Arg were 150% 
higher in patients with ulcerative colitis than in healthy individuals; levels of ornithine and lysine, which are 
also transported by CATs, were elevated as well, leading to competitive inhibition of arginine uptake. In the 
present study, AS II increased cellular L-Arg uptake without L-Arg supplementation. These findings suggest that 
enhancement of cellular L-Arg uptake, rather than L-Arg supplementation, may be a better strategy for treat-
ing IBD. L-glutamine supplementation has been shown to contribute to beneficial effects in a dextran sulfate 
sodium-induced colitis model37. The effect of AS II on L-glutamine absorption warrants further study.
L-Arg-mediated activation of the mTOR pathway improves intestinal cell migration and epithelial wound 
healing14, and was confirmed in genetically defined mouse models38. We found that AS II activated mTOR and its 
downstream targets, S6K and 4E-BP1. AS II increased protein synthesis in a concentration- and time-dependent 
manner, contributing to accelerated cell proliferation and wound healing. We confirmed the findings using lysine, 
a competitive inhibitor of L-arg uptake and rapamycin, a specific mTOR inhibitor. The mTOR signaling path-
way is activated by several amino acids, including L-Arg and L-leucine39,40. Future studies should also assess the 
effect of AS II on other amino acids, such as L-leucine. In addition, the CATs protein levels may not be equal to 
the activity transport capacity. Our results show L-Arg uptake peaks at 6 h that are consistent with the previous 
study that the protein kinase C (PKC) activator 12-O-tetradecanoylphorbol 13-acetate (TPA), stimulated system 
y + arginine transport activity in Caco-2 cells with transport capacity (Vmax) between 6–12 h34. In addition, 
absorption of cationic amino acids is largely dependent on y+ transport system, such as CAT1 and CAT241. It 
suggests AS II might promote the activity of CATs via the PKC pathway. However, the relationship between CATs 
levels and activity requires further investigation.
Figure 6. Proposed mechanism of astragaloside II (AS II) action on intestinal epithelial wound repair.
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In conclusion, AS II promotes intestinal epithelial repair by enhancing L-Arg uptake and activating the mTOR 
pathway. These findings suggest that AS II may be effective in relieving colitis.
Methods
Materials. A. membranaceus var. mongholicus was authenticated by Dr. H.C. Lin at the National Defense 
Medical Center, where a voucher specimen (NDMCP no. 1000901) has been deposited. L-Arg, L-lysine (Sigma-
Aldrich, St. Louis, MO, USA), L-[3H]-Arg, L-[3H]-leucine (American Radiolabeled Chemicals, St. Louis, MO, 
USA), and Ultima Gold liquid scintillation cocktails (PerkinElmer, Waltham, MA, USA) were used in the study.
Preparation of AS II. Dried root powder of Radix Astragali (9.5 kg) was soaked in 95% ethanol (20 L × 7), 
yielding a 756.25-g solution of Radix Astragali extract with evaporation under reduced pressure. The extract was 
then partitioned between n-BuOH-H2O and n-hexane-90% MeOH to yield 90% MeOH layer (334.68 g). The 90% 
MeOH fraction was subjected to medium-pressure liquid chromatography and eluted with an H2O-MeOH gra-
dient system, yielding three fractions. Fraction 2 (83.93 g) was further chromatographed on silica gel and eluted 
with CHCl3-MeOH-H2O (10:5:1) to yield AS II (1.68 g), which was identified using spectral data in the literature 
(Fig. 1A)42,43.
Cell culture. The human intestinal epithelial cell line Caco-2, a widely used model for studying the intestinal 
barrier, permeability, and wound healing44, was purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle’s medium (DMEM) with regular supplements.
Scratch wound assay. The assay was performed as described previously45. Briefly, Caco-2 cells were seeded 
in 24-well plates (2 × 105 cells/well) and allowed to reach confluence. Scratch wounds were made using a sterile 
10-μL pipette tip to create a straight cell-free line simulating a wound. After scratching, the cells were rinsed gen-
tly with phosphate-buffered saline (PBS) to remove detached cells. Next, cells were incubated with AS II in 5% 
CO2 at 37 °C. Cell migration was measured using photomicrography equipment (Leica Microsystems, Wetzlar, 
Germany) to compare the wound area 0, 12, 24, 36, and 48 hr after making the scratch.
Cell proliferation assay. Cell viability was assessed using a cell counting kit (CCK-8, Dojindo, Kumamoto, 
Japan) as described previously46. Briefly, Caco-2 cells (5 × 103 cells/well) were seeded in 96-well plates and incu-
bated in serum-free medium with various concentrations of AS II for 48 hr. The medium was then removed, and 
10 μL of CCK-8 in 90 μL of PBS were added to the cells for 2 hr. Absorbance was measured at 450 nm using a 
microplate reader (Molecular Devices, Sunnyvale, CA, USA).
L-Arg uptake assay. The assay was carried out as described previously11. Briefly, Caco-2 cells (2.5 × 104 cells/
well) were seeded in 24-well plates. Cells were cultured for 7 days after reaching confluence to allow differenti-
ation. The cells were then rinsed three times with transport buffer and incubated in transport buffer containing 
0.1 mM L-Arg and 1 μCi/mL L-[3H]-Arg for 5 min. The buffer was then removed; cells were rinsed three times 
with cold PBS and dissolved in 300 μL lysis buffer (1 N NaOH) for 1 hr at room temperature. Tissue L-Arg uptake 
measurement was performed as described previously7. A 1.5-cm section of intestinal or colonic tissue was dis-
sected and immediately incubated in transport buffer containing 0.1 mM L-Arg and 1 μCi/mL L-[3H]-Arg for 
5 min. The transport buffer was then removed; the tissues were rinsed three times with cold PBS and then lysed in 
500 μL 0.1 NHNO3 by gently shaking for 24 hr at room temperature. A 200-μL aliquot of the lysate was then col-
lected and mixed with 2 mL of liquid scintillation cocktails. Radioactivity was measured with a scintillation coun-
ter (TopCount, Packard BioScience, Meriden, CT, USA). L-Arg uptake is expressed as nmol/mg of protein/min.
De novo protein synthesis assay. The assay was described in a previous study47. Briefly, Caco-2 cells were 
seeded in 24-well plates (5 × 104 cells/well) and cultured for 7 days after reaching confluence. Cells were incubated 
in DMEM containing 1 μCi/ml [3H]-leucine for 4 hr and then rinsed three times with cold PBS. Next, cells were 
dissolved in 200 μL lysis buffer and precipitated with 10% trichloroacetic acid (TCA) for 10 min. After centrifu-
gation at 12,000 g for 5 min, the supernatant was discarded and the protein pellet was rinsed with 10% TCA and 
then dissolved in 300 μL NaOH (1 N). The solution (200 μL) was mixed with 2 mL of liquid scintillation cocktails. 
Protein synthesis was measured with a scintillation counter (TopCount, Packard BioScience).
Animal study protocol. Male C57BL/6JNarl 5-week-old (18–22 g) mice were purchased from the National 
Laboratory Animal Center (Taipei, Taiwan). Animal feeding and experimental procedures were approved by 
the Institutional Animal Care and Use Committee of the National Defense Medical Center (certificate number: 
IACUC-13–302) and performed in accordance with the relevant guidelines and regulations48. The mice were 
gavaged with 1 mL saline or AS II (10 mg/kg) once daily for 11 consecutive days. TNBS (100 mg/kg) was adminis-
tered via the rectum on the 8th day49. The mice were anesthetized with pentobarbital sodium (i.p. 70 mg/kg), and 
blood samples were collected from the orbital sinus. At the end of the experiment (11th day), the animals were 
euthanized using CO2 to allow harvesting of tissues. The intestine and colon were dissected.
MPO activity in colon tissue. MPO activity was assayed as previously described50. In brief, the tissue was 
lysed and freeze-thawed for three cycles in extraction buffer (1:20, w/v). Homogenates were then centrifuged 
at 14,000 rpm for 20 min. Ten microliters of supernatant were collected and mixed with 190 μL assay buffer 
(1.68 mM 3,3′,5,5′-tetramethylbenzidine and 0.00015% hydrogen peroxide). MPO activity was determined at 
650 nm using a microplate reader (Molecular Devices).
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Intestinal permeability assay. The assay was performed as described previously51. Briefly, the mice were 
fasted for 8 hr and then gavaged with FITC-dextran (50 mg/100 g; Sigma-Aldrich) 4 hr after fasting. Blood sam-
ples were collected from the retro-orbital sinus and centrifuged at 12,000 g for 20 min. Serum was measured at 
excitation and emission wavelengths of 490 and 520 nm, respectively, using a fluorescence microtiter plate reader 
(POLARstar Galaxy; BMG Labtech, Ortenberg, Germany).
Western blot analysis. This method was described in our previous study48. Cells were plated in 6-well plates 
(1 × 106 cells/well) and treated accordingly. Cells were then harvested in 0.2 mL of RIPA lysis buffer, separated by 
10% SDS-PAGE, and transferred to PVDF membranes (Millipore, Billerica, MA, USA). Immunoblotting was per-
formed using primary antibodies against CAT1, CAT2 (Abcam, Cambridge, UK), p-mTOR, mTOR, p-p70S6K, 
p70S6K, p-4E-BP1, 4E-BP1 (Cell Signaling Technology, Beverly, MA, USA), and the housekeeper β-actin 
(Millipore). The signals were visualized with an enhanced chemoluminescence kit (Amersham Biosciences, Little 
Chalfont, UK) followed by exposure of the blots to X-ray film.
Histology. A histological examination was performed following a method described previously50. Intestinal 
tissues were soaked in 10% formaldehyde solution for 24 hr, then stained with hematoxylin and eosin.
Statistical analysis. All data represent the mean ± SEM. Significant differences between group means 
were determined by one-way ANOVA followed by a Bonferroni post hoc test using SPSS version 22 (IBM SPSS, 
Armonk, NY, USA). p < 0.05 was considered statistically significant.
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